Philips, HeartFlow Cut FFR R&D, Commercial Deal
Executive Summary
HeartFlow has signed another deal with one of the medical imaging giants to promote its HeartFlow FFRct Analysis technology for diagnosing coronary heart disease, this time with Dutch group Philips. The collaboration will further expand Philips' intravascular imaging offerings, a space in which it is focused on becoming a leader.
You may also be interested in...
Market Intel: Increasingly Less-Invasive Diagnostic Techs To Disrupt Interventional Cardio Market
The global market for diagnostic and guided interventional cardiology products is expected to reach $4.8bn by 2021, and is driven in large part by the rising elderly population and increasing burden of cardiovascular disease (CVD). Meddevicetracker expects that intracardiac echocardiography (ICE), guide wire-based intravascular stenosis assessment (FFR) and optical coherence tomography (OCT) systems will drive overall market growth, given their high demand, which is supported by clinical evidence needed to bring cost savings and improved outcomes. Physicians' preference for using noninvasive and minimally invasive diagnostic techniques in cases where results are inconclusive is also changing the landscape of innovation. In this feature, we'll take a closer look at the overall market and its regional perspective, the competitive landscape of the three fastest-growing segments ICE, FFR and OCT, and the latest emerging technologies, as well as provide insight into what physicians think of these technologies.
Spectranetics Gives Philips Adjacent Territory In Image-Guided Therapy
The plum in the middle of Philips' intense period of M&A this summer was the €1.9 billion purchase of Spectranetics, which, combined with Philips Volcano, should create a $1 billion+ devices business within the image-guided therapy group by 2020. IGT senior vice president and general manager Bert van Meurs explains the rationale behind the deal, and what's next for Philips.
Philips Grows Image-Guided Intervention Focus With Spectranetics Buy
In its second acquisition this month and fourth this year, Philips is buying US device maker Spectranetics Corp. for about $2bn to add laser atherectomy catheters to its vascular imaging line-up.